All In Biotech

Drug Trial Radar · NCT00433589

Genetic Testing or Clinical Assessment in Determining the Need for Chemotherapy in Women With Breast Cancer That Involves No More Than 3 Lymph Nodes

MINDACT (Microarray In Node-Negative and 1 to 3 Positive Lymph Node Disease May Avoid Chemotherapy): A Prospective, Randomized Study Comparing the 70-Gene Signature With the Common Clinical-Pathological Criteria in Selecting Patients for Adjuvant Chemotherapy in Breast Cancer With 0 to 3 Positive Nodes

Last checked: Nov 19, 2026Latest source record: Nov 17, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 6,600 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

6,600

Planned (sponsor's estimate)

Start

Feb 2007

Primary completion

Mar 2020

Study completion Mar 2020

Sponsor

Sponsor type
Research network
Collaborators
Agendia; Breast International Group; Roche Pharma AG; Novartis; Sanofi
First posted
Feb 12, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
Female only, from 18 years, up to 120 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Estrogen can cause the growth of breast cancer cells. Hormone therapy using tamoxifen may fight breast cancer by blocking the use of estrogen by the tumor cells. Letrozole may fight breast cancer by lowering the amount of estrogen the body makes. Giving chemotherapy and hormone therapy after surgery may kill any tumor cells that remain after surgery. It is not yet known whether genetic testing is more effective than clinical assessment in determining the need for chemotherapy in treating breast cancer. PURPOSE: This randomized phase III trial is studying genetic testing to see how well it works compared with clinical assessment in determining the need for chemotherapy in women with breast cancer that is either node-negative or involves no more than 3 lymph nodes.

Conditions

  • Breast Cancer

Interventions

  • anthracycline-basedDrug

  • docetaxel and capecitabineDrug

  • tamoxifenDrug

  • LetrozoleDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Distant metastasis-free survival at 5 yearsTime frame: from enrollment/randomization
  2. Disease-free survival (DFS)Time frame: from enrollment/randomization
  3. DFSTime frame: from enrollment/randomization

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital

    Amsterdam, Netherlands

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.